So a tin hat wearer in ATHE has found a red flag in their view. In UMSARS graph they have stated that the placebo started at a different point score, therefore believes this does not qualify as a good result, and the company was needing to release this to get money as they had none, but yet couldnt highlight any other issues...even moving these starting numbers to the placebo, there is still a distinct difference in final scores...thoughts
Ann: Positive ATH434 Phase 2 Results Led By Clinical Efficacy, page-161
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.3¢ |
Change
-0.001(7.14%) |
Mkt cap ! $119.6M | |||
| Open | High | Low | Value | Volume |
| 1.4¢ | 1.5¢ | 1.3¢ | $123.8K | 8.854M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 36 | 22048002 | 1.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.4¢ | 980000 | 4 |
View Market Depth
| Last trade - 16.10pm 07/08/2025 (20 minute delay) ? |
| ATH (ASX) Chart |